Clinical trials: COPD Asthma
Copd, Asthma
Strados System at Center of Excellence
Listening to breath sounds with the stethoscope/auscultation is used by pulmonary physicians in conjunction with pulmonary function, signs and symptoms, oxygen saturation and diagnostic testing to admit, follow and discharge…
- Conditions
- Copd, Asthma, Covid19
- Trial name
- NCT04485741
- Testing
- RESP
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Strados Labs, Inc.
Asthma Acute, COPD Exacerbation Acute
Rademikibart IV for Acute Asthma and COPD Exacerbation
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
- Trial name
- NCT07705737
- Testing
- Rademikibart
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Connect Biopharm LLC
Pulmonary Disease, Chronic Obstructive
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
The purpose of this study is to evaluate the dose-response of 4 doses of umeclidinium bromide in combination with fluticasone furoate compared with fluticasone furoate monotherapy in chronic obstructive pulmonary disease…
- Trial name
- NCT02164539
- Testing
- FF, UMEC, VI
- Where
- 67 sites in United States, Argentina and 5 more
- Volunteers
- 338 people
- Sponsor
- GlaxoSmithKline
Patients With Asthma-COPD Overlap Syndrome (ACOS)
Non-interventional Study of COPD Patients With Asthma Overlap Syndrome in Viet Nam and Taiwan
The purpose of this study to determine the proportion and clinical characteristics of COPD patients with asthma symptoms (ACOS) and describe current practices in diagnosis and management in Viet Nam and Taiwan.
- Trial name
- NCT02878252
- Where
- 5 sites in Taiwan, Vietnam
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma
This is a Phase 1b, single center study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3923868 following repeat doses in mild asthmatics during experimental human…
- Trial name
- NCT05398198
- Testing
- GSK3923868
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Rhinovirus
Discovering New Treatments for Asthma and COPD. A New Human Rhinvovirus for Human Challenge
A GMP rhinovirus was manufactured according to GMP and then characterised in human volunteers in the human viral challenge model.
- Trial name
- NCT02522832
- Testing
- Titre 1, Titre 2, Titre 3
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hvivo
Dyspnea
Vibration Response Imaging (VRI) in Dyspnea Patients Presenting to the ED
For the patient with acute dyspnea in the ED, early differentiation between CHF and non-CHF causes is essential for proper management.
- Trial name
- NCT01206621
- Where
- 8 sites in United States, Israel
- Volunteers
- 530 people
- Sponsor
- Deep Breeze
Asthma,, Chronic Obstructive Pulmonary Disease
Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct
The correct use of inhalation devices is an inclusion criterion for all studies comparing inhaled treatments. In real life, however, patients may make many errors with their usual inhalation device, which may negate the benefits…
- Trial name
- NCT01426893
- Where
- 5 sites in Serbia
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Asthma Copd
A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment
A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary…
- Trial name
- ESPIRE (NCT04233190)
- Testing
- Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
- Where
- Brazil
- Volunteers
- 472 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma, COPD
The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
- Trial name
- NCT03858686
- Testing
- FP-025 capsules
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.